Healthcare May 20, 2022 10:53 AM (GMT+8) · EqualOcean
Yiouda health on May 20, Haizheng pharmaceutical announced last night that it had signed the strategic cooperation agreement and the entrusted production framework agreement with Shanghai Wangshi Biomedical Technology Co., Ltd. (hereinafter referred to as "Wangshi biology"), a subsidiary of Junshi biology, to establish strategic cooperation in the fields of product processing, production, international registration and market development of small molecule innovative new drug vv116, so as to realize complementary advantages, mutual benefit and win-win results The strategic goal of common development. It is reported that oral anti novel coronavirus drug vv116 is in the phase III clinical research stage of international multi center, and a number of registered clinical studies for patients with mild, moderate and severe novel coronavirus pneumonia are in progress. At present, vv116 has been approved in Uzbekistan for the treatment of moderate and severe covid-19 patients.

This text is a result of machine translation.